
Inizio helped Tonix successfully launch the first FDA-approved therapy in its class in almost two decades by delivering an integrated, AI-enabled commercialization program spanning analytics, field operations, and launch readiness.

Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.

What does a high-value medical affairs organization look like in a world of constrained resources, increasingly capable artificial intelligence (AI) and easier access to scientific information? For medical affairs leaders...

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...

Remibrutinib reduced relapse rates and improved disease progression rates

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.